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Porto Alegre, Brazil; and Pisa, ItalyOBJECTIVES The aim of this study was to deﬁne the performance of lung ultrasound (LUS)
compared with clinical assessment, natriuretic peptides, and echocardiography, to evaluate decompen-
sation in patients with systolic heart failure (HF) in an outpatient clinic.
BACKGROUND Evaluation of pulmonary congestion in chronic HF is challenging. LUS has been
recently proposed as a reliable tool for the semiquantiﬁcation of extravascular lung water through assess-
ment of B-lines.
METHODS This was a cohort study of patients with moderate to severe systolic HF. Receiver-
operating characteristic (ROC) analyses were performed to compare LUS with a previously validated clin-
ical congestion score (CCS), amino-terminal portion of B-type natriuretic peptide (NT-proBNP), E/e0 ratio,
chest x-ray, and 6-min walk test.
RESULTS Ninety-seven patients were enrolled. Decompensation was present in 57.7% of patients
when estimated by CCS, 68% by LUS, 53.6% by NT-proBNP, and 65.3% by E/e0 $15. The number of
B-lines was correlated to NT-proBNP (r ¼ 0.72; p < 0.0001), E/e0 (r ¼ 0.68; p < 0.0001), and CCS
(r ¼ 0.43; p < 0.0001). In ROC analyses, considering as reference for decompensation a combined
method (E/e0 $15 and/or NT-proBNP >1,000 pg/ml), LUS yielded a C-statistic of 0.89 (95% conﬁdence
interval: 0.82 to 0.96), providing the best accuracy with a cutoff $15 B-lines (sensitivity 85%, speciﬁcity
83%). A systematic approach using CCS, E/e0, NT-proBNP, chest x-ray, and 6-min walk test in different
combinations as reference for decompensation also corroborated this cutoff and found a similar accuracy
for LUS.
CONCLUSIONS In an HF outpatient clinic, B-lines were signiﬁcantly correlated with more estab-
lished parameters of decompensation. A B-line $15 cutoff could be considered for a quick and reliable
assessment of decompensation in outpatients with HF. (J Am Coll Cardiol Img 2013;6:1141–51) ª 2013
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6MWT = 6-min walk test
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1142espite impressive improvements in treat- METHODS
ment strategies over the past 2 decades,
heart failure (HF) morbidity and mortality
remain substantially high worldwide (1).
Pulmonary congestion, rather than low cardiac
output, is considered the leading cause of hospital
admissions and death among patients with HF
(2,3).
Physical examination is crucial for titrating
medical treatment in these patients (4). Unfortu-
nately, this traditional assessment has a good
speciﬁcity but is not sensitive enough to detect
elevated cardiac ﬁlling pressures (5). Recently,
different clinical congestion scores (CCS) have
been developed to evaluate signs of congestion in
patients with HF (6–9). However, data comparing
these scores with more established tools of
decompensation are scarce. The amino-terminalcore
ic
rly
water
nal
icportion of B-type natriuretic peptide
(NT-proBNP) is a powerful neurohor-
monal predictor of prognosis in HF (10)
and can be used to titrate therapy (11).
Echocardiography can be also used to
noninvasively measure left ventricular
(LV) ﬁlling pressures (12): the ratio of
early diastolic mitral inﬂow velocity to
early diastolic velocity of the mitral
annulus (E/e0) is one of the most
frequently used parameters to assess LV
pressures and estimate hemodynamic
congestion (13,14).
Lung ultrasound (LUS) through
B-line evaluation (formerly ultrasound
lung comets) has been recently proposed
as a simple, noninvasive, and semi-
quantitative tool to assess extravascularlung water (EVLW) (15). B-lines have been
shown to be correlated to NT-proBNP (16) and
E/e0 levels in patients with acute dyspnea (17) and
after a stress test (18). LUS can also identify
clinically silent pulmonary edema (19,20), sug-
gesting that it could be added to the clinical
evaluation to improve hemodynamic proﬁling and
treatment optimization.
To date, no study has evaluated LUS perfor-
mance for the assessment of pulmonary conges-
tion in outpatients with HF. The aim of this
study was to compare B-lines with more tradi-
tional methods, such as clinical evaluation, NT-
proBNP, and echocardiographic parameters, and
determine its performance to assess decompen-
sation in a cohort of outpatients with moderate to
severe systolic HF.Study design and population. We included 97
consecutive patients followed up in an HF outpa-
tient clinic at the Cardiology Institute of Rio
Grande do Sul, Brazil, between November 2011
and October 2012. Inclusion criteria were: 1) age
>18 years; 2) LV systolic HF diagnosis for more
than 6 months regardless of cause as deﬁned by the
Framingham criteria (21) and satisfying the Euro-
pean Society of Cardiology guidelines (22); 3)
moderate to severe systolic HF (ejection fraction
<45%); 4) no prior diagnosis of pulmonary ﬁbrosis;
and 5) absence of congenital heart disease (Fig. 1).
Clinical assessment, NT-proBNP analysis, LUS,
echocardiography, and chest x-ray (CXR) were
independently performed at the clinical appoint-
ment (index evaluation) within a maximum 5-h
time delay between the ﬁrst and last examinations.
All patients ﬁlled out the Minnesota Living With
Heart Failure Questionnaire, a 100-mm analogue
visual dyspnea scale, and underwent a 6-min walk
test (6MWT) in accordance with standardized
methodology. The study protocol was approved by
the ethics committee of our institution (protocol
UP4467.11). All participants provided written
informed consent. We followed the STARD
(Standards for the Reporting of Diagnostic) state-
ment for studies of diagnostic accuracy (23).
Clinical congestion score. A previously validated
clinical assessment score (7) was used to objectively
classify the patients on clinical grounds only. The
CCS was calculated by summing up the values
obtained in the clinical assessment of HF signs and
symptoms, consisting of the following: orthopnea
(0 to 4), pulmonary rales (0 to 4), increased central
venous pressure (0 to 4), peripheral edema (0 to 4),
third heart sound (0 to 1), hepatojugular reﬂux
(0 to 1), and functional class according to New York
Heart Association functional classiﬁcation (1 to 4).
The CCS could vary from 1 to 22 points, and pa-
tients with $3 points were considered decom-
pensated (7).
Natriuretic peptide analysis. Peripheral venous
blood samples were obtained from each patient
before the index evaluation. NT-proBNP analysis
was performed using the Elecsys 2010 analyzer
(Roche Diagnostics, Mannheim, Germany). An
NT-proBNP >1,000 pg/ml was considered a cutoff
marker for decompensated HF.
Echocardiography and LUS. Comprehensive trans-
thoracic echocardiography at rest was performed in
all patients using a Vivid-I GE Vingmed ultrasound
Patients Follow Up At Heart Failure Outpatient Clinic
(n = 132)
Patients Evaluated By Lung Ultrasound
(n = 97)
B-lines < 15 (n = 31) B-lines ≥ 15 (n = 66)
Patients Excluded Due to:
- Congenital Heart Disease (n = 20)
- Pulmonary Fibrosis (n = 1)
- Left Ventricle Ejection Fraction > 45% (n = 12)
- Age < 18 Years (n = 2)
Evaluation Not Performed
E/e’ Ratio (n = 2)
NT-proBNP (n = 0)
CCS (n = 0)
CXR* (n = 1)
6mWT† (n = 9)
Not Decompensated According to:
E/e’ < 15 (n = 23)
NT-proBNP ≤ 1000 pg/mL (n = 28)
CCS (n = 19)
CXR (n = 29)
6mWT (n = 23)
Decompensated According to:
E/e’ ≥ 15 (n = 54)
NT-proBNP > 1000 pg/mL (n = 49)
CCS (n = 44)
CXR (n = 34)
6mWT (n = 39)
Figure 1. Study Enrollment
*Not possible to evaluate the chest x-ray plain ﬁlms due to an overpenetration regimen. yTest not performed due to physical disability or
medical contraindication. Online Video 1 shows normal lung ultrasound pattern, some A-lines are visible. Online Video 2 shows abnormal lung
ultrasound evidencing B-lines, as sign of extravascular lung water. 6mWT ¼ 6-min walk test; CCS ¼ clinical congestion score; CXR ¼ chest
x-ray; E/e0 ¼ ratio of early diastolic mitral inﬂow velocity to early diastolic velocity of mitral annulus; NT-proBNP ¼ amino-terminal portion of
B-type natriuretic peptide.
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1143with commercially available cardiac probes (2.5 to
3.5 MHz) to record all examinations. Further in-
dependent evaluation was performed ofﬂine. LV
volumes and ejection fraction were measured by the
modiﬁed biplane Simpson method according to the
American Society of Echocardiography and adjusted
for body surface area (24). Diastolic function was
determined from the pattern ofmitral and pulmonary
venous ﬂow velocities measured by pulsed Doppler
echocardiography and complemented by septal and
lateral mitral annular velocity measured by tissue
Doppler imaging (14). The LV ﬁlling pressure was
determined from E/e0 ratio, with the formula 1.24
(E/e0) þ 1.9 (13). From the anterograde pulmonary
ﬂow acceleration time, we also estimated the meanpulmonary artery pressure and left atrial (LA) pres-
sure using the Mahan and Henry formula (25).
Diastolic dysfunction and mitral regurgitation were
staged according to the European Association of
Cardiovascular Imaging guidelines (14,26).
After the aforementioned routine examination, all
patients underwent LUS to assess the presence of B-
lines (27). AB-line was deﬁned as a discrete laser-like
vertical hyperechoic reverberation artifact that arises
from the pleural line extending to the bottom of the
screen without fading and moving synchronously
with lung sliding (Online Videos 1 and 2) (28). We
analyzed the anterior and lateral hemithoraces, scan-
ning along the parasternal, midclavicular, anterior
axillary, and midaxillary lines, as previously described
AB
C
Figure 2. Lung Ultrasound ROC Curves
(A) Receiver-operating characteristic (ROC) curve for lung ultra-
sound (LUS) and CCS with NT-proBNP >1,000 pg/ml as reference
for decompensated heart failure. (B) ROC curve for LUS and CCS
with E/e0 $15 as reference for decompensated heart failure.
(C) ROC curve for LUS and CCS with NT-proBNP >1,000 pg/ml and/
or E/e0 $15 as reference for decompensated heart failure.
AUC ¼ area under the concentration–time curve; CI = conﬁdence
interval; other abbreviations as in Figure 1.
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1144(28). A total of 28 chest sites were scanned, and the
total number of B-lines was recorded. Ninety-ﬁve
patients were analyzed in the supine or near-supine
position; 2 patients were orthopneic and the sitting
position was preferred. All LUS examinations were
recorded and reviewed in a blinded manner.
Chest x-ray. Chest radiographs were obtained in the
orthostatic posteroanterior and lateral projections. All
plain ﬁlms were independently evaluated by 2 radi-
ologists recording cardiothoracic index, heart vascular
pedicle and vena azygos width, LA enlargement,
cephalization, interstitial edema, alveolar edema,
pleural effusion, and overall congestion impression.
Statistical analysis. Continuous variables are
expressed as mean  SD or median (25th, 75th
percentiles), as appropriate. Categorical variables are
presented as counts and percentages. Univariate
comparisons were made by chi-square or 2-sample
Student t test, as appropriate. Differences in the
median NT-proBNP concentrations and median
number of B-lines were tested with Mann-Whitney
nonparametric test. The diagnostic utility of LUS in
detecting signiﬁcant pulmonary congestion was
determined using receiver-operating characteristic
(ROC) curves, assuming NT-proBNP>1,000 pg/ml,
E/e0 $15, CCS $3, congested CXR, and 6MWT
distance <300 m as references for decompensated
HF. The results were expressed using the
C-statistic. The best threshold was obtained by
selecting the point on the ROC curve that
maximized both sensitivity and speciﬁcity. The
correlation between conventional methods and B-
line number was assessed with a nonparametric
Spearman correlation coefﬁcient analysis. Statisti-
cal analyses were performed using SPSS statistics
version 19.0.0 (Chicago, Illinois).RESULTS
Determination of LUS cutoff. There is not a gold
standard tool in clinical practice to evaluate decom-
pensation, and multiple parameters are usually
combined to increase sensitivity. Therefore, we
considered the most used and established parameters
as reference to determine the LUS cutoff. Com-
bining NT-proBNP >1,000 pg/ml and/or E/e0 $15
yielded a C-statistic of 0.89 for LUS (95% conﬁ-
dence interval [CI]: 0.82 to 0.96), with the best
cutoff of $15 B-lines providing 84.9% sensitivity
(95% CI: 0.7 to 0.9) and 83.3% speciﬁcity (95% CI:
0.6 to 0.9) (Fig. 2). A systematic approach including
CXR, CCS, E/e0, NT-proBNP, and 6MWT in
different combinations (adapted from Gheorghiade
et al. [6]) was also used; the best accuracy was yielded
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1145by a cutoff $15 B-lines in 9 of 10 different analyses
(Online Appendix). This cutoff was also tested
assuming NT-proBNP >1,000 pg/ml as a sign of
decompensation, with a positive predictive value of
74.2% (95% CI: 0.6 to 0.8) and negative predictive
value of 90.3% (95% CI: 0.7 to 0.97). When using
E/e0 $15 as a reference for decompensation, NT-
proBNP and B-lines $15 had similar speciﬁcity
(72.7% and 69.7%, respectively), with a signiﬁcantly
better sensitivity for LUS (87.1%) compared with
NT-proBNP >1,000 pg/ml (66.1%).
Clinical, radiographic, and echocardiographic ﬁndings.
The main characteristics of the patients are listed in
Table 1. Decompensation was present in 53.6%
according to NT-proBNP, in 57.7% by CCS, and
in 37.5% by CXR. An elevated LA pressure esti-
mated by an E/e0 $15 was found in 65.3% of
patients. The sensitivity of CCS and CXR in
detecting elevated LA pressure was 67.1% and
50.8%, respectively. Due to pacemaker stimulation,
we were not able to obtain E/e0 and characterize
the diastolic function in 2 patients. Restrictive
diastolic dysfunction, pseudonormalization pat-
terns, and abnormal relaxation were identiﬁed in
41.7%, 28.1%, and 29.2% of patients, respectively.
Mitral regurgitation was recognized as mild in
61.9%, moderate in 13.4%, and severe in 2.1% of
patients.
LUS ﬁndings. LUS feasibility was 100%; mean
duration of the examination was 8.7  2.0 min.
Signiﬁcant pulmonary congestion was identiﬁed in
68% of patients by LUS (total number of B-lines
$15). Patients with NT-proBNP >1,000 pg/ml had
a signiﬁcantly higher number of B-lines compared
with patients with NT-proBNP #1,000 pg/ml
(54 36 vs. 17 17; p< 0.0001). A higher number
of B-lines was also found in patients with E/e0
$15 compared with patients with E/e0 <15 (50 
34 vs. 8  3; p < 0.0001). When stratiﬁed by
number of B-lines $15 and <15, patients showed
signiﬁcant differences between many parameters
(Table 2). All patients with B-lines $15 presented
a pattern of multiple bilateral B-lines, rather ho-
mogeneously distributed in all scanned sites (with
the exception of sites 18 and 19 occupied in some
patients by a larger cardiac area). In this group,
there was a signiﬁcant correlation between the
number of B-lines on the right and on the left
hemithorax (r ¼ 0.6; p < 0.0001), as well as a
similar number of positive ($3 B-lines) scans
(p < 0.0001). A B-line distribution graph is
shown in the Online Appendix.
Correlation among clinical, biochemical, and LUS
ﬁndings. The number of B-lines correlated withNT-proBNP values (r ¼ 0.72; p < 0.0001) (Fig. 3).
Using NT-proBNP as a reference for decompen-
sation, ROC analysis showed a C-statistic of 0.87
for LUS (95% CI: 0.8 to 0.94), with 86.5% sensi-
tivity (95% CI: 0.7 to 0.9) and 73.3% speciﬁcity
(95% CI: 0.6 to 0.8). The negative predictive value
was 82.5% (95% CI: 0.7 to 0.9), whereas the posi-
tive predictive value was 79% (95% CI: 0.6 to 0.9)
(Fig. 2). The dominant source of discordance was
due to abnormal LUS (number of B-lines $15) and
NT-proBNP #1,000 pg/ml. Of these 16 patients,
only 2 had an E/e0 <13. The only discordant case
with increased natriuretic peptide level and B-lines
<15 was associated with the absence of decompen-
sation according to all other methods (Online
Appendix). Because the NT-proBNP reference
value for decompensated HF is still a source of
disagreement, we also performed the analysis using
other cutoff points (Online Appendix).
A signiﬁcant correlation was found between
B-lines and E/e0 (r ¼ 0.68; p < 0.0001) (Fig. 2),
CXR (r ¼ 0.59; p < 0.0001), and CCS (r ¼ 0.43;
p < 0.0001) (Online Appendix). With E/e0 $15 as
a reference, ROC analysis showed a C-statistic of
0.85 for LUS (95% CI: 0.77 to 0.93), providing the
best accuracy with 82.3% sensitivity (95% CI: 0.7 to
0.9) and 75.8% speciﬁcity (95% CI: 0.6 to 0.9)
(Fig. 2). The negative predictive value was 69.4%
(95% CI: 0.5 to 0.8), whereas the positive predictive
value was 86.4% (95% CI: 0.7 to 0.9). The domi-
nant source of discordance was an abnormal LUS
(number of B-lines $15) and an E/e0 <13 (Online
Appendix).DISCUSS ION
This study showed that in an HF outpatient clinic,
B-lines were signiﬁcantly correlated with more
established parameters of decompensation, sug-
gesting that monitoring chronic HF by LUS can be
feasible and accurate in this population. Moreover,
our ﬁndings suggested a B-line $15 value as a
reliable cutoff in identifying patients with signiﬁcant
pulmonary congestion.
The recognition and quantiﬁcation of pulmonary
congestion are crucial steps in a thorough evaluation
of patients with HF in any clinical setting. LUS
seems to be a simple and accurate method for
assessing decompensation in an outpatient clinic.
The short examination time with 100% feasibility
allows this technique to be easily performed during
outpatient evaluation. In our study, the time needed
to perform each LUS examination was about twice
Table 1. Patient Main Characteristics
All
(n [ 97)
B-lines ‡15
(n [ 66)
B-lines <15
(n [ 31) p Value
Age, yrs 53  13 55  13 50  13 NS
White 78 (80) 52 (79) 26 (84) NS
Male 59 (61) 38 (58) 21 (68) NS
Body mass index, kg/m2 28  5 28  5 28  4 NS
Heart rate, beats/min 74  13 75  12 73  14 NS
Systolic arterial pressure, mm Hg 120  23 118  23 124  23 NS
Diastolic arterial pressure, mm Hg 75  14 75  14 77  14 NS
Hypertension 52 (53) 36 (54) 16 (51) NS
Dyslipidemia 43 (44) 30 (45) 13 (42) NS
Diabetes mellitus 22 (23) 17 (26) 5 (16) NS
Coronary artery disease 29 (30) 20 (30) 9 (29) NS
COPD 2 (2) 2 (3) d NS
Minnesota questionnaire score 39  22 42  23 33  18 NS
Heart disease etiology
Dilated cardiomyopathy 52 (54) 35 (53) 17 (55)
Post-ischemic 26 (27) 16 (24) 10 (32)
Hypertension 10 (10) 8 (12) 2 (6.5) NS
Myocarditis 4 (4) 2 (3) 2 (6.5)
Toxicitydalcohol 3 (3) 3 (4) d
Arrhythmia 1 (1) 1 (2) d
Chagas 1 (1) 1 (2) d
NYHA functional class 2.1  0.8 2.3  0.8 1.9  0.7
II 49 (50) 34 (51) 15 (48)
III 22 (23) 16 (24) 6 (19) 0.023
IV 6 (6) 6 (9) d
Left ventricular ejection fraction, % 28  7 27  8 31  6 0.004
Indexed left atrium volume, ml/m2 44  26 47  29 37  18 NS
Electrocardiogram
Sinus rhythm 75 (77) 47 (71) 28 (90) 0.029
Atrial ﬁbrillation 16 (16) 13 (20) 3 (10) NS
QRS $150 ms 40 (42) 31 (48) 9 (29) NS
CC, ml/min/1.73 m2 100  41 97  42 108  40
<30 1 (1) 1 (1.5) d
30–59 15 (15) 11 (15) 5 (16) NS
$60 81 (83) 55 (83) 26 (84)
Sodium, mEq/l 139  3 139  3 139  3 NS
Hematocrit (%)/hemoglobin (g/dl) 40  4/13  1.5 40  4/13  1.5 40  4/13  1.4 NS/NS
Beta-blockers 92 (95) 62 (94) 30 (97) NS
Target dose 32 (35) 21 (34) 11 (37) NS
ACE inhibitors 64 (66) 43 (65) 21 (68) NS
Target dose 23 (36.5) 13 (31) 10 (48) NS
Angiotensin II receptor blockers 22 (23) 17 (26) 5 (16) NS
Target dose 15 (71) 11 (69) 4 (80) NS
Continued on the next page
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Table 1. Continued
All
(n [ 97)
B-lines ‡15
(n [ 66)
B-lines <15
(n [ 31) p Value
Aldosterone antagonist 51 (53) 32 (48) 19 (61) NS
Diuretics 60 (62) 41 (62) 19 (61) NS
Digoxin 49 (50) 36 (54) 13 (42) NS
Calcium antagonists 5 (5) 2 (3) 3 (10) NS
Nitrates 14 (14) 8 (12) 6 (19) NS
Hydralazine 5 (5) 3 (4) 2 (6) NS
Statins 37 (38) 24 (36) 13 (42) NS
Aspirin 37 (38) 24 (36) 13 (42) NS
Oral anticoagulants 16 (16) 12 (18) 4 (13) NS
Amiodarone 10 (10) 8 (12) 2 (6) NS
Pacemaker/ICD 14 (14) 12 (18) 2 (6) NS
CRT 5 (5) 4 (6) 1 (3) NS
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; CC ¼ creatinine clearance; COPD ¼ chronic obstructive pulmonary disease; CRT ¼ cardiac resynchronization therapy; ICD ¼
implantable cardioverter deﬁbrillator; NS ¼ nonsigniﬁcant; NYHA ¼ New York Heart Association.
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1147the time that has been previously reported (16,29).
This prolongation was mainly because all LUS clips
were recorded to be independently and blindly
double-reviewed.
Evaluation of decompensation in chronic HF
is challenging, even for highly skilled clinicians
(30,31). Signs and symptoms provided only a poor
sensitivity for the detection of elevated left heart
pressures in our series, with similar data (58%) re-
ported in the literature (30). According to a previous
study, the main use of a CCS was to predict a decline
in the 6-month event-free survival in patients with
clear evidence of decompensation (relative risk¼ 4.8;
p¼ 0.02) (7). However, decompensation is clinically
silent in most patients with chronic HF and is often
not recognized until conditions develop that require
hospital admission; this critical delay in diagnosis
justiﬁes the need for more sensitive diagnostic tools
(3). The CXR remains by far the most widely used
test for detecting pulmonary edema (32), but the
absence of radiological evidence for decompensated
HF in the chronic outpatient evaluation does not
exclude elevated ﬁlling pressures (31). This ﬁnding
was conﬁrmed in our study, with only half of patients
with an E/e0 $15 being identiﬁed by CXR. Ac-
cording to the American Heart Association/Amer-
ican College of Cardiology guidelines, serial CXRs
are not recommended in the assessment of pulmo-
nary congestion in chronic HF (4,22). Moreover,
serial CXR implies radiation exposure, which should
be minimized whenever possible (33,34). Invasive
monitoring is the gold standard for evaluatinghemodynamic congestion in HF. However, this
form of monitoring is clinically impractical, making
the use of other noninvasive tools as surrogates for
estimating hemodynamic congestion more attractive
options.
We showed that B-lines measured by LUS
correlated well with NT-proBNP and E/e0. This
correlation was not surprising because the presence
of B-lines implies more EVLW due to augmented
LV ﬁlling pressures (17,27,35). Our ﬁndings are
consistent with those of previous works from other
groups, showing that the number of B-lines and
their changes after therapy correlate with CXR water
score (36), natriuretic peptides (16,37), indexes of
diastolic dysfunction (17,38), and intrathoracic
impedance monitoring (39). The appropriate refer-
ence value of NT-proBNP to use remains a matter of
disagreement in the literature. We chose 1,000 pg/ml
as a cutoff based on studies that related this value to
increased morbidity and mortality (40–45). Because
these tests evaluate different pathophysiological
mechanisms, it is plausible that their concordance is
not complete. Both natriuretic peptides and E/e0
identify hemodynamic congestion, a condition that
precedes pulmonary congestion, which is identiﬁed
by B-lines (46,47). The strength of B-line evalua-
tion is to provide direct insight into the pulmonary
interstitium and to be able to differentiate a con-
dition of pure hemodynamic congestion from pul-
monary interstitial edema (15). Furthermore,
pulmonary congestion is usually, but not always,
related to high LV ﬁlling pressure, which may
Table 2. Heart Failure Decompensation Parameter Evaluation
All
(n [ 97)
B-lines ‡15
(n [ 66)
B-lines <15
(n [ 31) p Value
E/e0 23  16 28  18 13  4 <0.0001
LA pressure by E/e0 ratio* 30.5  20.3 36.5  22.0 17.9  5.0 <0.0001
MPAPy 39.1  10.9 42.5  9.8 32.0  9.8 <0.0001
LA pressurez 22.1  10.5 25.2  9.6 15.0  8.8 <0.0001
NT-proBNP, pg/ml 2,232  2,838 3,070  3,100 450  359 <0.0001
B-lines 36.6  34.2 50.0  34.2 7.9  3.3 <0.0001
6-min walk test distance, m 276  147 241  141 340  139 <0.001
Analogue visual dyspnea scale, mm 20  23 24  25 13  16 <0.05
Clinical congestion on CCS 56 (57.7) 44 (66.7) 12 (38.7) <0.01
Pulmonary congestion on CXR 36 (37) 34 (52) 2 (6) <0.0001
Values are mean  SD or n (%). *Nagueh formula. yMahan formula. zHenry formula.
CCS ¼ clinical congestion scale; CXR ¼ chest x-ray; E/e0 ¼ ratio of early diastolic mitral inﬂow velocity to early diastolic velocity of mitral annulus; LA ¼ left atrium;
MPAP ¼ mean pulmonary arterial pressure; NT-proBNP ¼ amino-terminal portion of B-type natriuretic peptide.
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1148explain some cases of normal NT-proBNP level
and/or E/e0 with abnormal LUS (48).
After analyzing LUS and NT-proBNP discor-
dant cases, we realized that these patients were in a
“gray zone” for the diagnosis of decompensation
by conventional methods. Thus, LUS with num-
ber of B-lines $15 cutoff appeared to be an
additional method to aid in the detection of
EVLW, with results similar to those of the
multiple-parameter combined assessment. A cut-
off based on B-line number has never been pre-
viously proposed in outpatients and is somewhat
arbitrary. It was at ﬁrst chosen on the basis of our
clinical experience of LUS in patients with HF butFigure 3. Lung Ultrasound Correlation
Correlation between the number of B-lines and NT-proBNP levels (A) athen conﬁrmed by statistical analysis. This cutoff
of 15 B-lines showed the best accuracy when the
reference for decompensation was the combined
approach of NT-proBNP >1,000 pg/ml and/or
E/e0 $15.
LUS is also able to evaluate dynamic changes in
EVLW content (37,49). Moreover, this technique
is faster to perform, is less expensive, and has lower
technical requirements compared with a full echo-
cardiography examination. All of these features
make it an attractive clinical tool to introduce in an
outpatient HF clinic.
Prospective large-scale randomized (LUS
guided vs. standard therapy) outcome studies arend E/e0 values (B). Abbreviations as in Figures 1 and 2.
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1149needed to understand whether B-lines could be
implemented in the routine clinical evaluation of
outpatients, helping to detect an earlier state of
decompensation.
Study limitations. The lack of a true gold standard
to verify the presence or absence of pulmonary
congestion is an important limitation that does not
allow the determination of the real accuracy of LUS,
compared with other tests. However, we compared
LUS with the most established tools that are used in
the real clinical arena in outpatients and found a
similar performance.
Sample size is another limitation of this study,
and our series may not represent the average patient
with HF. Ideally, this study should be repeated in a
general cardiology clinic and should include patients
with mild systolic HF and patients with only dia-
stolic HF. Furthermore, the detection of B-lines
does not necessarily imply their cardiogenic origin.
Pulmonary ﬁbrosis and noncardiogenic pulmonary
edema, such as acute respiratory distress syndrome,
may also result in the presence of B-lines, implying
a differential diagnosis that was not present in our
study population (50,51).CONCLUS IONS
In a moderate to severe systolic HF outpatient
clinic, B-lines evaluated by LUS were signiﬁcantly
correlated with the CCS, E/e0, and NT-proBNP
levels, accurately suggesting decompensation with
a B-line $15 cutoff. Given its accuracy, LUS could
be considered a reliable tool for the assessment of
pulmonary congestion in patients with HF; it could
be used as an extension of the physical examination
and to differentiate hemodynamic from pulmonary
congestion. This technique is appealing for the
outpatient clinic because it uses simple technology
(including pocket-sized devices) and is rapid to
perform and interpret. As a possible clinical impli-
cation, pharmacological therapy could be tailored as
soon as the patient, although asymptomatic, shows a
signiﬁcant increase in the number of B-lines.Reprint requests and correspondence: Dr. Marcelo Haertel
Miglioranza, Unidade de Pesquisa, Instituto de Car-
diologia do Rio Grande do Sul, Av. Princesa Isabel, 370,
Porto Alegre/RS, CEP 90620-000, Brazil. E-mail:
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